Annual CFO
-$394.09 M
-$60.80 M-18.24%
December 31, 2023
Summary
- As of February 8, 2025, NTLA annual cash flow from operations is -$394.09 million, with the most recent change of -$60.80 million (-18.24%) on December 31, 2023.
- During the last 3 years, NTLA annual CFO has fallen by -$344.17 million (-689.56%).
- NTLA annual CFO is now -1191.38% below its all-time high of $36.11 million, reached on December 31, 2016.
Performance
NTLA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$84.84 M
-$26.65 M-45.80%
September 30, 2024
Summary
- As of February 8, 2025, NTLA quarterly cash flow from operations is -$84.84 million, with the most recent change of -$26.65 million (-45.80%) on September 30, 2024.
- Over the past year, NTLA quarterly CFO has increased by +$16.54 million (+16.32%).
- NTLA quarterly CFO is now -225.59% below its all-time high of $67.55 million, reached on June 30, 2016.
Performance
NTLA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$356.74 M
+$16.54 M+4.43%
September 30, 2024
Summary
- As of February 8, 2025, NTLA TTM cash flow from operations is -$356.74 million, with the most recent change of +$16.54 million (+4.43%) on September 30, 2024.
- Over the past year, NTLA TTM CFO has increased by +$34.16 million (+8.74%).
- NTLA TTM CFO is now -822.57% below its all-time high of $49.37 million, reached on June 30, 2016.
Performance
NTLA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NTLA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.2% | +16.3% | +8.7% |
| 3 y3 years | -689.6% | -30.5% | -69.4% |
| 5 y5 years | -543.3% | -233.4% | -245.5% |
NTLA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -75.1% | at low | -55.2% | +29.7% | -58.5% | +12.0% |
| 5 y | 5-year | -689.6% | at low | -247.8% | +29.7% | -912.4% | +12.0% |
| alltime | all time | -1191.4% | at low | -225.6% | +29.7% | -822.6% | +12.0% |
Intellia Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$84.84 M(+45.8%) | -$356.74 M(-4.4%) |
| Jun 2024 | - | -$58.19 M(-51.8%) | -$373.28 M(-7.9%) |
| Mar 2024 | - | -$120.66 M(+29.7%) | -$405.42 M(+2.9%) |
| Dec 2023 | -$394.09 M(+18.2%) | -$93.05 M(-8.2%) | -$394.09 M(+0.8%) |
| Sep 2023 | - | -$101.38 M(+12.2%) | -$390.90 M(+6.2%) |
| Jun 2023 | - | -$90.32 M(-17.4%) | -$368.05 M(+1.4%) |
| Mar 2023 | - | -$109.33 M(+21.7%) | -$362.81 M(+8.9%) |
| Dec 2022 | -$333.29 M(+48.1%) | -$89.87 M(+14.4%) | -$333.29 M(+11.8%) |
| Sep 2022 | - | -$78.53 M(-7.7%) | -$298.07 M(+4.7%) |
| Jun 2022 | - | -$85.09 M(+6.6%) | -$284.56 M(+12.7%) |
| Mar 2022 | - | -$79.80 M(+46.0%) | -$252.46 M(+12.2%) |
| Dec 2021 | -$225.03 M(+350.9%) | -$54.65 M(-15.9%) | -$225.03 M(+6.8%) |
| Sep 2021 | - | -$65.02 M(+22.7%) | -$210.60 M(+20.9%) |
| Jun 2021 | - | -$52.98 M(+1.2%) | -$174.14 M(+173.2%) |
| Mar 2021 | - | -$52.38 M(+30.2%) | -$63.74 M(+27.7%) |
| Dec 2020 | -$49.91 M(-51.7%) | -$40.23 M(+40.9%) | -$49.91 M(+30.2%) |
| Sep 2020 | - | -$28.56 M(-149.7%) | -$38.35 M(+8.8%) |
| Jun 2020 | - | $57.42 M(-249.0%) | -$35.24 M(-70.7%) |
| Mar 2020 | - | -$38.55 M(+34.5%) | -$120.33 M(+16.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$103.24 M(+68.5%) | -$28.66 M(+12.6%) | -$103.24 M(+24.2%) |
| Sep 2019 | - | -$25.45 M(-8.1%) | -$83.12 M(+18.5%) |
| Jun 2019 | - | -$27.68 M(+29.0%) | -$70.12 M(+8.0%) |
| Mar 2019 | - | -$21.45 M(+151.3%) | -$64.94 M(+6.0%) |
| Dec 2018 | -$61.26 M(-6.2%) | -$8.54 M(-31.4%) | -$61.26 M(-17.2%) |
| Sep 2018 | - | -$12.45 M(-44.6%) | -$74.03 M(-5.7%) |
| Jun 2018 | - | -$22.50 M(+26.6%) | -$78.47 M(+9.5%) |
| Mar 2018 | - | -$17.77 M(-16.6%) | -$71.65 M(+9.8%) |
| Dec 2017 | -$65.28 M(-280.8%) | -$21.31 M(+26.1%) | -$65.28 M(+11.8%) |
| Sep 2017 | - | -$16.89 M(+7.8%) | -$58.38 M(+18.9%) |
| Jun 2017 | - | -$15.68 M(+37.6%) | -$49.10 M(-243.8%) |
| Mar 2017 | - | -$11.40 M(-20.9%) | $34.13 M(-5.5%) |
| Dec 2016 | $36.11 M(-2148.2%) | -$14.41 M(+89.4%) | $36.11 M(-19.8%) |
| Sep 2016 | - | -$7.61 M(-111.3%) | $45.03 M(-8.8%) |
| Jun 2016 | - | $67.55 M(-817.0%) | $49.37 M(-408.5%) |
| Mar 2016 | - | -$9.42 M(+71.6%) | -$16.01 M(+807.9%) |
| Dec 2015 | -$1.76 M | -$5.49 M(+68.1%) | -$1.76 M(-147.3%) |
| Sep 2015 | - | -$3.27 M(-250.3%) | $3.73 M(-46.7%) |
| Jun 2015 | - | $2.17 M(-54.9%) | $7.00 M(+45.1%) |
| Mar 2015 | - | $4.82 M | $4.82 M |
FAQ
- What is Intellia Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Intellia Therapeutics?
- What is Intellia Therapeutics annual CFO year-on-year change?
- What is Intellia Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly CFO year-on-year change?
- What is Intellia Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Intellia Therapeutics?
- What is Intellia Therapeutics TTM CFO year-on-year change?
What is Intellia Therapeutics annual cash flow from operations?
The current annual CFO of NTLA is -$394.09 M
What is the all time high annual CFO for Intellia Therapeutics?
Intellia Therapeutics all-time high annual cash flow from operations is $36.11 M
What is Intellia Therapeutics annual CFO year-on-year change?
Over the past year, NTLA annual cash flow from operations has changed by -$60.80 M (-18.24%)
What is Intellia Therapeutics quarterly cash flow from operations?
The current quarterly CFO of NTLA is -$84.84 M
What is the all time high quarterly CFO for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly cash flow from operations is $67.55 M
What is Intellia Therapeutics quarterly CFO year-on-year change?
Over the past year, NTLA quarterly cash flow from operations has changed by +$16.54 M (+16.32%)
What is Intellia Therapeutics TTM cash flow from operations?
The current TTM CFO of NTLA is -$356.74 M
What is the all time high TTM CFO for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM cash flow from operations is $49.37 M
What is Intellia Therapeutics TTM CFO year-on-year change?
Over the past year, NTLA TTM cash flow from operations has changed by +$34.16 M (+8.74%)